Semarion Introduces SemaCyte Multiplexing Platform to Enhance Cell Assay Data Quality and Speed During Drug Discovery
Retrieved on:
Wednesday, March 20, 2024
Research, Medical Devices, Health Technology, Stem Cells, Biotechnology, Health, Pharmaceutical, Science, Oncology, AZD5363, Cell, Platform, Entrepreneurship, Drug discovery, Material, Partnership, Cell biology, Interference microscopy, Nanomagnet, University, University of Cambridge, HCI, CRISPR, Cavendish Laboratory, Engineering, Mobile phone
Designed specifically to augment microplate-based high-content imaging (HCI) approaches, the platform enables in situ multiplexing of adherent cells using the Company’s proprietary microcarriers, SemaCytes, to enhance both the quality and speed of data generation.
Key Points:
- Designed specifically to augment microplate-based high-content imaging (HCI) approaches, the platform enables in situ multiplexing of adherent cells using the Company’s proprietary microcarriers, SemaCytes, to enhance both the quality and speed of data generation.
- The SemaCyte Multiplexing Platform uses optical barcodes to tag and differentiate individual cells and cell types while preserving natural morphology, with each microcarrier capable of carrying millions of unique identifiers.
- The Multiplexing Platform can be used across a broad range of applications, including target identification, compound screening and compound profiling.
- The Multiplexing Platform has been developed to further leverage Semarion’s innovative microcarrier technology, SemaCytes, in advancing drug discovery workflows.